Latest news with #Pluvicto®
Cision Canada
03-07-2025
- Business
- Cision Canada
Quebec implements public reimbursement of Pluvicto® - a defining milestone for radioligand therapy in Canada Français
Pluvicto ® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as more jurisdictions recognize radioligand as a critical therapy for advanced prostate cancer MONTREAL, July 3, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto ® (lutetium (177 Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for eligible patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). This new funding milestone marks a significant expansion in access to this innovative radioligand therapy. With reimbursement now secured in Quebec, Pluvicto ® is publicly funded in the country's four most populous provinces, bringing new treatment opportunities to Canadians living with PSMA-positive mCRPC who have previously undergone androgen receptor pathway inhibition and taxane-based chemotherapy. "We have been looking forward to this day for some time now as it represents a significant breakthrough for people in Quebec who have been longing for access to this much-needed treatment," said Laurent Proulx, President and CEO of PROCURE. "This progress brings real hope to countless patients and highlights how vital it is to make cutting-edge therapies available across Canada. We urge all provinces to keep moving forward so that every eligible patient, no matter where they live, can benefit from the best possible care and quality of life." Reimbursement in Quebec gives physicians more flexibility to integrate radioligand therapy into the treatment path for appropriate patients with advanced disease. "Public reimbursement of Pluvicto ® in Quebec is a meaningful advancement for individuals with PSMA-positive mCRPC who have already undergone multiple lines of treatment," said Dr. Frédéric Arsenault, President, Association des médecins spécialistes en médecine nucléaire du Québec. "Expanding access to radioligand therapy, a growing pillar in cancer care, marks a shift toward a new era of precision treatment that reflects the rapidly advancing oncology landscape. This decision helps close a longstanding treatment gap and will allow patients to receive timely treatment and care that offers hope and the potential to improve quality of life 1." Pluvicto ® is now publicly reimbursed in seven provinces: Quebec, Ontario, Alberta, British Columbia, Nova Scotia, Saskatchewan, and Newfoundland and Labrador. Each provincial listing extends access to more patients across the country and signals growing recognition of radioligand therapy as an important addition to advanced prostate cancer treatment options. "This announcement adds to the growing momentum behind the adoption of Pluvicto ® and radioligand therapy in prostate cancer care," said Mark Vineis, Country President, Novartis Pharmaceuticals Canada Inc. "It sends a strong signal that this approach is being recognized as a key part of the evolving cancer treatment landscape. We'll continue working closely with other jurisdictions to maintain this progress and help ensure every eligible patient across the country can access this important treatment option." Approved by Health Canada in August 2022, Pluvicto ® is the first targeted radioligand therapy for the treatment of PSMA-positive mCRPC in Canada 2. About Pluvicto ® Pluvicto ® (lutetium (177 Lu) vipivotide tetraxetan injection) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy 2. It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle) 2. After administration into the bloodstream, Pluvicto ® binds to target cells, including prostate cancer cells that express PSMA, a transmembrane protein 2. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells disrupting their ability to replicate and/or triggering cell death 2. About Novartis Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit Pluvicto is a registered trademark. SOURCE Novartis Pharmaceuticals Canada Inc.
Business Wire
28-05-2025
- Business
- Business Wire
Archeus Technologies and Wisconsin Alumni Research Foundation Partner to Advance Radiopharmaceutical Therapy ART-101 into Clinical Development for Prostate Cancer
MADISON, Wis.--(BUSINESS WIRE)-- Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies, and the Wisconsin Alumni Research Foundation (WARF), the patenting and licensing arm of the University of Wisconsin–Madison (UW), today announced a strategic collaboration to advance ART-101 – a promising receptor-based targeting molecule – into clinical development. ART-101 was discovered and developed at the Advanced Radiotheranostics Lab at UW–Madison, led by Dr. Reinier Hernandez, assistant professor of medical physics at the University of Wisconsin School of Medicine and Public Health. Aided by robust support from WARF through the WARF Accelerator, ART-101 has demonstrated enhanced pharmacology in preclinical studies, including significantly higher tumor uptake and retention relative to FDA-approved prostate cancer treatment Pluvicto ® (177Lu-PSMA-617). It has also shown superior pharmacokinetics, dosimetry and normal tissue toxicity profiles. Through a collaboration agreement with WARF, Archeus Technologies will lead Phase 1 clinical development of this asset with trial initiation planned for 2025. ART-101 is a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule. It is being evaluated as a radiopharmaceutical agent with the potential to deliver alpha-emitting isotopes with greater tolerability compared with current standards of care. 'With strong preclinical data supporting the continued development of ART-101, Archeus is eager to lead the evaluation of this novel candidate through first-in-human studies,' said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. 'Leveraging our team's proven experience ushering new radiopharmaceutical agents from concept through clinical translation, paired with our close collaboration with UW as a world-class radiopharmaceutical research organization, Archeus is uniquely positioned to progress ART-101 into the next stage of development. This asset adds to our Phase 1-ready portfolio of differentiated radiopharmaceutical therapies with the potential to provide curative responses to cancers that are particularly challenging to treat.' 'WARF is committed to investing in cutting-edge technologies and therapeutic candidates, like ART-101, that have significant potential to advance the theranostics landscape as well as treatment options for patients in need,' said Jeanine Burmania, senior director of intellectual property and licensing at WARF. 'Encouraging preclinical data suggest that ART-101 could help increase lifespan and be more effective in treating prostate cancer than current therapies. We're pleased to partner with Archeus Technologies to continue the development of this innovative asset and look forward to better understanding its role to potentially improve outcomes for prostate cancer patients.' ART-101 is compatible with multiple therapeutic isotopes, including actinium-225, lutetium-177 and terbium-161. When paired with these isotopes, preclinical data show that ART-101 provides significant potential benefit that could lead to improved outcomes for prostate cancer patients. About Archeus Technologies Archeus Technologies is a company developing differentiated radiopharmaceutical therapies for some of the most difficult-to-treat cancers. Starting with its Phase 1-ready therapeutic candidate, ARC-706, the company has assembled a growing pipeline of novel radiopharmaceutical therapy agents and companion diagnostic assets with the potential to provide curative responses to patients with advanced disease. Archeus is led by an executive team with proven radiopharmaceutical expertise and a demonstrated record of advancing innovative agents from discovery through clinical development. In addition, Archeus has a long-standing strategic collaboration with the University of Wisconsin-Madison (UW), a global leader in radiopharmaceuticals and theranostics. To learn more, visit About WARF Celebrating a century of service in 1925, the Wisconsin Alumni Research Foundation (WARF) patents and licenses discoveries from UW-Madison research, manages an investment portfolio generated from licensing and investment proceeds, and provides annual grants to the University of Wisconsin-Madison and the Morgridge Institute for Research to support further scientific investigation and research. By driving collaborations among researchers, investors, industry and entrepreneurs, WARF commercializes innovations from campus through various initiatives. WARF Accelerator improves the commercialization potential of university intellectual property through industry engagement and investment in proof-of-concept milestones to validate market potential, demonstrate commercial value and de-risk technology. WARF Therapeutics partners with UW-Madison and Morgridge Institute researchers employing an industry-focused approach to improve the value propositions of drug candidates. WARF Ventures is an early-stage venture fund that invests in startups based on UW/WARF technologies. Learn more at
